Biosimilars Clinical Trials Investigations Landscape: 2007–2016

Biosimilars Clinical Trials Investigations Landscape: 2007–2016

09:27, April 7 2017

By GlobalData

GlobalData's latest white paper offers a unique insight into the biosimilars clinical trial market

This whitepaper provides a review of global clinical trials for biosimilars initiated between 2007 and 2016 from the Clinical Trials Database of GlobalData's Pharma Intelligence Center. An analyses of the data landscapes of these trials is provided alongside an analysis on the different molecules of biosimilars: specifically, the antibodies and others being investigated in these trials.

Companies mentioned in this whitepaper include Accelsiors, Amgen, BIOCAD, Boehringer Ingelheim, CEBIS International, Celltrion, Cliantha Research, Ecron Acunova, Eli Lilly, the Fred Hutchinson Cancer Research Center, Hospira, ICON, INC Research, Lambda Therapeutic Research, Merck, Nexus Clinical Research, Nucleus Network, Parexel, Pharmaceutical Product Development, PRA Health Sciences, Pfizer, Quintiles IMS, Region Skane, Reliance Life Sciences, Samsung Bioepis, Sandoz, Seaview Research, SGS Life Science, Sun Yat-sen University, University Hospital Tuebingen, and Yonsei University.

Summary of Contents

  • Biosimilar Clinical Trial Landscape.................................................................................................. 4
  • Introduction................................................................................................................................... 4
  • Clinical Trials by Phase and Sponsor Type, 2007-2016..................................................................... 5
  • Single-Country and Multinational Biosimilar Trials, 2007-2016............................................................ 6
  • Average Size of Biosimilar Clinical Trials, 2007-2016..........................................................................7
  • Biosimilar Clinical Trials by Therapy Area, 2007-2016........................................................................ 8
  • Top Indications for Biosimilar Clinical Trials, 2007-2016 .................................................................... 8
  • Biosimilar Clinical Trials by Status, 2007-2016.................................................................................. 9
  • Top Industry Sponsors for Biosimilar Clinical Trials, 2007-2016 ........................................................ 10
  • Top Contract Research Organizations Involved in Biosimilar Clinical Trials, 2007-2016 ........................ 11
  • Top Drugs Investigated in Biosimilar Clinical Trials, 2007-2016........................................................... 11
  • Antibody Biosimilar Trials Versus Other Trials, 2007-2016................................................................. 12

Download Whitepaper

Biosimilars Clinical Trials Investigations Landscape: 2007–2016
More Whitepapers